After Cantor Fitzgerald and Cowen & Co. gave Gilead Sciences (NASDAQ: GILD) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Cory Kasimov maintained a Buy rating on Gilead Sciences yesterday. The company’s shares closed last Monday at $64.31.
According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 6.1% and a 47.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Global Blood Therapeutics, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $77.46 average price target, implying a 19.1% upside from current levels. In a report issued on January 2, Cowen & Co. also maintained a Buy rating on the stock with a $85.00 price target.
The company has a one-year high of $70.50 and a one-year low of $60.89. Currently, Gilead Sciences has an average volume of 6.15M.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.